Teo Adrian Kee Keong, Lau Hwee Hui, Valdez Ivan Achel, Dirice Ercument, Tjora Erling, Raeder Helge, Kulkarni Rohit N
Section of Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Brigham and Women's Hospital, Harvard Stem Cell Institute, Harvard Medical School, One Joslin Place, Boston, MA 02215, USA; Discovery Research Division, Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos #06-07, Singapore 138673, Singapore; School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore.
Discovery Research Division, Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos #06-07, Singapore 138673, Singapore.
Stem Cell Reports. 2016 Mar 8;6(3):357-67. doi: 10.1016/j.stemcr.2016.01.007. Epub 2016 Feb 11.
Patients with an HNF1B(S148L/+) mutation (MODY5) typically exhibit pancreatic hypoplasia. However, the molecular mechanisms are unknown due to inaccessibility of patient material and because mouse models do not fully recapitulate MODY5. Here, we differentiated MODY5 human-induced pluripotent stem cells (hiPSCs) into pancreatic progenitors, and show that the HNF1B(S148L/+) mutation causes a compensatory increase in several pancreatic transcription factors, and surprisingly, a decrease in PAX6 pancreatic gene expression. The lack of suppression of PDX1, PTF1A, GATA4, and GATA6 indicates that MODY5-mediated pancreatic hypoplasia is mechanistically independent. Overexpression studies demonstrate that a compensatory increase in PDX1 gene expression is due to mutant HNF1B(S148L/+) but not wild-type HNF1B or HNF1A. Furthermore, HNF1B does not appear to directly regulate PAX6 gene expression necessary for glucose tolerance. Our results demonstrate compensatory mechanisms in the pancreatic transcription factor network due to mutant HNF1B(S148L/+) protein. Thus, patients typically develop MODY5 but not neonatal diabetes despite exhibiting pancreatic hypoplasia.
携带HNF1B(S148L/+)突变(MODY5)的患者通常表现出胰腺发育不全。然而,由于无法获取患者材料且小鼠模型不能完全重现MODY5,其分子机制尚不清楚。在此,我们将MODY5人诱导多能干细胞(hiPSC)分化为胰腺祖细胞,并表明HNF1B(S148L/+)突变导致几种胰腺转录因子代偿性增加,且令人惊讶的是,PAX6胰腺基因表达降低。对PDX1、PTF1A、GATA4和GATA6缺乏抑制表明MODY5介导的胰腺发育不全在机制上是独立的。过表达研究表明,PDX1基因表达的代偿性增加是由于突变型HNF1B(S148L/+)而非野生型HNF1B或HNF1A。此外,HNF1B似乎不直接调节葡萄糖耐量所需的PAX6基因表达。我们的结果证明了由于突变型HNF1B(S148L/+)蛋白在胰腺转录因子网络中存在代偿机制。因此,尽管患者表现出胰腺发育不全,但通常发展为MODY5而非新生儿糖尿病。